Author: admin

Keratoconus Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix

“Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the 7MM.

DelveInsight’s “Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Forecast

 

Some of the key facts of the Keratoconus Market Report: 

  • The Keratoconus market size was valued approximately USD 3 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2021, the expected total diagnosed prevalent population of Keratoconus throughout the seven primary markets was 1,818,900
  • In the United States, it was discovered that there were approximately 743,000 diagnosed cases of keratoconus in 2021.
  • In Japan, there were around 257,600 diagnosed cases of Keratoconus in 2021.
  • NORD estimates that the prevalence of keratoconus in the general population in the United States in 2019 was 54.5 per 100,000 people, or roughly 1 in 2,000 people. People who have a family history of keratoconus are more likely to get the illness than members of the general public.
  • In August 2022, iVeena entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for KC.
  • In September 2022, CXL Opthhalmics presented its Phase II data and according to the data 80% of patients maintained or improved corrected distance visual acuity 12 months post-operation and 89%of patients 21 years or younger showed stable or improved vision at 12 months.
  • Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others
  • Key Keratoconus Therapies: Riboflavin 5′-Phosphate, IVMED-80, Dextenza, and others
  • The Keratoconus epidemiology based on gender analyzed that Keratoconus affects both males and females equally
  • The Intacs Device from Price Vision Group and the Photrexa and Photrexa Viscousa from Avedro are among the US FDA-approved treatments for KC. Intacs are ocular medical inserts intended to reduce or eliminate myopia and astigmatism in patients with KC, whereas Photrexa and Photrexa Viscous are photoenhancers recommended for use with the KXL System in corneal collagen cross-linking for the treatment of patients with progressive KC.
  • The Keratoconus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Keratoconus pipeline products will significantly revolutionize the Keratoconus market dynamics.

 

Keratoconus Overview

The eye (ocular) condition known as keratoconus (KC) is characterized by the cornea’s gradual thinning and alterations in form. The cornea is the outermost layer of the eye that is clear and thin. It often has a dome shape. A cone-shaped protrusion forms toward the center of the cornea in the places where the cornea is thinning the fastest due to slowly progressive corneal thinning.

 

Get a Free sample for the Keratoconus Market Report:

https://www.delveinsight.com/report-store/keratoconus-market

 

Keratoconus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Keratoconus Epidemiology Segmentation:

The Keratoconus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Keratoconus
  • Prevalent Cases of Keratoconus by severity
  • Gender-specific Prevalence of Keratoconus
  • Diagnosed Cases of Episodic and Chronic Keratoconus

 

Download the report to understand which factors are driving Keratoconus epidemiology trends @ Keratoconus Epidemiology Forecast

 

Keratoconus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Keratoconus market or expected to get launched during the study period. The analysis covers Keratoconus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Keratoconus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Keratoconus Therapies and Key Companies

  • Riboflavin 5′-Phosphate: Glaukos Corporation
  • IVMED-80: iVeena Delivery Systems
  • Dextenza: Ocular Therapeutix, Inc.

 

Discover more about therapies set to grab major Keratoconus market share @ Keratoconus Treatment Market

 

Keratoconus Market Strengths

  • Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight

Keratoconus Market Opportunities

  • There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market.

 

Scope of the Keratoconus Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others
  • Key Keratoconus Therapies: Riboflavin 5′-Phosphate, IVMED-80, Dextenza, and others
  • Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies
  • Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Keratoconus Unmet Needs, KOL’s views, Analyst’s views, Keratoconus Market Access and Reimbursement 

 

To know more about Keratoconus companies working in the treatment market, visit @ Keratoconus Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Keratoconus Market Report Introduction

2. Executive Summary for Keratoconus

3. SWOT analysis of Keratoconus

4. Keratoconus Patient Share (%) Overview at a Glance

5. Keratoconus Market Overview at a Glance

6. Keratoconus Disease Background and Overview

7. Keratoconus Epidemiology and Patient Population

8. Country-Specific Patient Population of Keratoconus 

9. Keratoconus Current Treatment and Medical Practices

10. Keratoconus Unmet Needs

11. Keratoconus Emerging Therapies

12. Keratoconus Market Outlook

13. Country-Wise Keratoconus Market Analysis (2019–2032)

14. Keratoconus Market Access and Reimbursement of Therapies

15. Keratoconus Market Drivers

16. Keratoconus Market Barriers

17.  Keratoconus Appendix

18. Keratoconus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Keratoconus Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix

Metastatic Melanoma Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Evaxion Biotech, InxMed, AiVita Biomedical

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Metastatic Melanoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

 

Some of the key takeaways from the Metastatic Melanoma Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years. 
  • Metastatic Melanoma companies working in the treatment market are TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment 
  • Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.   
  • In October 2023, Perspective Therapeutics, a company specializing in medical technology and radiopharmaceuticals, has initiated the enrollment of the initial group of patients for its Phase I/IIa dose escalation investigation of ²¹²Pb-VMT01, aiming to address MC1R-positive metastatic melanoma.
  • In July 2022, Regeneron Pharmaceuticals has commenced a clinical study entitled “Phase III Investigation of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Compared to Pembrolizumab in Individuals with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma.
  • In July 2022, Bristol-Myers Squibb Company has disclosed that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has proposed the endorsement of the combined fixed-dose mixture of nivolumab and relatlimab. This recommendation pertains to the initial therapy of advanced (unresectable or metastatic) melanoma in adults and adolescents aged 12 years and above.
  • In March 2022, Nektar Therapeutics and Bristol Myers Squibb Company provided an update after the initial examination of the Phase 3 PIVOT IO-001 study, which assesses the combination therapy of bempegaldesleukin with Opdivo (nivolumab). This analysis compares the doublet therapy to Opdivo monotherapy as the primary treatment for unresectable or metastatic melanoma in individuals who have not received prior treatment.

 

Metastatic Melanoma Overview

Metastatic melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells have spread from the initial site of the skin or mucous membrane to other parts of the body. This typically involves the lymph nodes, organs, or distant tissues.

 

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

 

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:

  • TILT 123: TILT Biotherapeutics
  • AV-MEL-1: AiVita Biomedical
  • IMM-1-104: Immuneering Corporation
  • UV1: Ultimovacs ASA
  • APX005: MPyxis Oncology
  • EVX 01: Evaxion Biotech
  • HBI-8000: HUYABIO International, LLC.
  • IO102-IO103: IO Biotech
  • Fianlimab: Regeneron Pharmaceuticals

 

Metastatic Melanoma Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Metastatic Melanoma Molecule Type

Metastatic Melanoma Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Metastatic Melanoma Pipeline Therapeutics Assessment

  • Metastatic Melanoma Assessment by Product Type
  • Metastatic Melanoma By Stage and Product Type
  • Metastatic Melanoma Assessment by Route of Administration
  • Metastatic Melanoma By Stage and Route of Administration
  • Metastatic Melanoma Assessment by Molecule Type
  • Metastatic Melanoma by Stage and Molecule Type

 

DelveInsight’s Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies

 

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:

Key companies developing therapies for Metastatic Melanoma are – Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC.,  IO Biotech,  Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline,  Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

 

Metastatic Melanoma Pipeline Analysis:

The Metastatic Melanoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
  • Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies

 

Metastatic Melanoma Pipeline Market Drivers

  • Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

 

Metastatic Melanoma Pipeline Market Barriers

  • However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

 

Scope of Metastatic Melanoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Metastatic Melanoma Companies: TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others
  • Key Metastatic Melanoma Therapies: TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
  • Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies
  • Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers 

 

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Melanoma Report Introduction

2. Metastatic Melanoma Executive Summary

3. Metastatic Melanoma Overview

4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Melanoma Pipeline Therapeutics

6. Metastatic Melanoma Late Stage Products (Phase II/III)

7. Metastatic Melanoma Mid Stage Products (Phase II)

8. Metastatic Melanoma Early Stage Products (Phase I)

9. Metastatic Melanoma Preclinical Stage Products

10. Metastatic Melanoma Therapeutics Assessment

11. Metastatic Melanoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Melanoma Key Companies

14. Metastatic Melanoma Key Products

15. Metastatic Melanoma Unmet Needs

16 . Metastatic Melanoma Market Drivers and Barriers

17. Metastatic Melanoma Future Perspectives and Conclusion

18. Metastatic Melanoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Melanoma Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Evaxion Biotech, InxMed, AiVita Biomedical

Smoking Cessation and Nicotine Addiction Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Inc., Cipla, Novartis, GlaxoSmithKline

“Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the 7MM.

DelveInsight’s “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. 

 

To Know in detail about the Smoking Cessation and Nicotine Addiction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Smoking Cessation and Nicotine Addiction Market Forecast

 

Some of the key facts of the Smoking Cessation and Nicotine Addiction Market Report: 

  • The Smoking Cessation and Nicotine Addiction market size was valued approximately USD 2,311 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, there were 46,814,225 prevalent cases of smoking cessation in the 7MM, with 23,145,916 of those cases occurring in the US. During the predicted timeframe (2023-2032), these cases should decline
  • In the United States, tobacco usage was widely frequent in 31,414,398 males and 20,084,615 females in 2022, though this number is expected to decline over the course of the forecast period
  • In the US, the age groups with the highest rates of tobacco use in 2022 were 25-44 years of age with 22,659,566 cases, followed by 45-64 years with 18,539,645 cases, 65 and over with 5,664,891 cases, and 18-24 years with 4,634,911 cases
  • In Japan, there were 20,842,435 prevalent cases of tobacco usage as of 2022. During the projected period (2023-2032), these cases are anticipated to decline at a considerable CAGR
  • The prevalence of nicotine dependence cases among cigarette smokers in the EU4 and the UK was 35,049,259 in 2022; these instances are anticipated to decline over the course of the study
  • During the Smoking Cessation and Nicotine Addiction forecast period (2023–2032), AXS-05, Cytisinicline (Cytisine), and NFL-101 are anticipated to enter the market. Since the 1960s, Cytisine has been used to treat nicotine addiction and smoking cessation in a number of Central and Eastern European nations. It is less expensive than other cessation drugs and has minimal known negative effects.
  • Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
  • Key Smoking Cessation and Nicotine Addiction Therapies: Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
  • The Smoking Cessation and Nicotine Addiction epidemiology based on gender analyzed that, in the US the prevalence of tobacco use is higher in males than females
  • The Smoking Cessation and Nicotine Addiction market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Smoking Cessation and Nicotine Addiction pipeline products will significantly revolutionize the Smoking Cessation and Nicotine Addiction market dynamics. 

 

Smoking Cessation and Nicotine Addiction Overview

When tobacco use is repeated, a group of behavioural, cognitive, and physiological phenomena known as nicotine/tobacco dependence emerge. These phenomena typically include a strong desire to smoke, difficulty in controlling one’s use, persistence in smoking despite negative effects, giving smoking a higher priority than other activities and obligations, increased tolerance, and occasionally a physical withdrawal state. 

 

Get a Free sample for the Smoking Cessation and Nicotine Addiction Market Report 

https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market

 

Smoking Cessation and Nicotine Addiction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Smoking Cessation and Nicotine Addiction Epidemiology Segmentation:

The Smoking Cessation and Nicotine Addiction market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Smoking Cessation and Nicotine Addiction
  • Prevalent Cases of Smoking Cessation and Nicotine Addiction by severity
  • Gender-specific Prevalence of Smoking Cessation and Nicotine Addiction
  • Diagnosed Cases of Episodic and Chronic Smoking Cessation and Nicotine Addiction

 

Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction epidemiology trends @ Smoking Cessation and Nicotine Addiction Epidemiology Forecast

 

Smoking Cessation and Nicotine Addiction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Smoking Cessation and Nicotine Addiction market or expected to get launched during the study period. The analysis covers Smoking Cessation and Nicotine Addiction market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Smoking Cessation and Nicotine Addiction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Smoking Cessation and Nicotine Addiction Therapies and Key Companies

  • Cytisinicline: Achieve Life Sciences
  • NFL-101: NFL Biosciences SAS
  • EMB-001: Embera NeuroTherapeutics
  • CX-101: Currax Pharmaceuticals
  • OMS-405: Omeros Corporation
  • AXS-05: Axsome Therapeutics

 

Discover more about therapies set to grab major Smoking Cessation and Nicotine Addiction market share @ Smoking Cessation and Nicotine Addiction Treatment Market

 

Smoking Cessation and Nicotine Addiction Market Strengths

  • Advancements in treatment with emerging drugs that are expected to have novel MoAs and rapid onset of action

 

Smoking Cessation and Nicotine Addiction Market Opportunities

  • Lucrative opportunities are available to address unmet therapeutic needs in the smoking and nicotine deaddiction drug market as the existing pipeline remains insufficient

 

Scope of the Smoking Cessation and Nicotine Addiction Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
  • Key Smoking Cessation and Nicotine Addiction Therapies: Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
  • Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Smoking Cessation and Nicotine Addiction current marketed and Smoking Cessation and Nicotine Addiction emerging therapies
  • Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction market drivers and Smoking Cessation and Nicotine Addiction market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement  

 

To know more about Smoking Cessation and Nicotine Addiction companies working in the treatment market, visit @ Smoking Cessation and Nicotine Addiction Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Smoking Cessation and Nicotine Addiction Market Report Introduction

2. Executive Summary for Smoking Cessation and Nicotine Addiction

3. SWOT analysis of Smoking Cessation and Nicotine Addiction

4. Smoking Cessation and Nicotine Addiction Patient Share (%) Overview at a Glance

5. Smoking Cessation and Nicotine Addiction Market Overview at a Glance

6. Smoking Cessation and Nicotine Addiction Disease Background and Overview

7. Smoking Cessation and Nicotine Addiction Epidemiology and Patient Population

8. Country-Specific Patient Population of Smoking Cessation and Nicotine Addiction 

9. Smoking Cessation and Nicotine Addiction Current Treatment and Medical Practices

10. Smoking Cessation and Nicotine Addiction Unmet Needs

11. Smoking Cessation and Nicotine Addiction Emerging Therapies

12. Smoking Cessation and Nicotine Addiction Market Outlook

13. Country-Wise Smoking Cessation and Nicotine Addiction Market Analysis (2019–2032)

14. Smoking Cessation and Nicotine Addiction Market Access and Reimbursement of Therapies

15. Smoking Cessation and Nicotine Addiction Market Drivers

16. Smoking Cessation and Nicotine Addiction Market Barriers

17.  Smoking Cessation and Nicotine Addiction Appendix

18. Smoking Cessation and Nicotine Addiction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Inc., Cipla, Novartis, GlaxoSmithKline

Multiple Sclerosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Sclerosis pipeline constitutes 100+ key companies continuously working towards developing 100+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Multiple Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Sclerosis Market.

 

Some of the key takeaways from the Multiple Sclerosis Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Multiple Sclerosis treatment therapies with a considerable amount of success over the years. 
  • Multiple Sclerosis companies working in the treatment market are ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others, are developing therapies for the Multiple Sclerosis treatment 
  • Emerging Multiple Sclerosis therapies in the different phases of clinical trials are- IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others are expected to have a significant impact on the Multiple Sclerosis market in the coming years.   
  • In January 2022, Immunic Therapeutics has commenced a multicenter clinical trial that includes a randomized, double-blind, placebo-controlled investigation. This study consists of both a blinded Main Treatment Period (MT) and an Open Label Period (OLE), aiming to assess the effectiveness, safety, and tolerance of IMU-838 in adult patients diagnosed with relapsing multiple sclerosis (RMS).
  • In June 2022, Immunic revealed additional supportive findings from its phase II EMPhASIS trial of the vidofludimus calcium formulation. The results indicated decreases in MRI lesions among patients diagnosed with relapsing multiple sclerosis (MS), coupled with a positive safety profile.

 

Multiple Sclerosis Overview

The most prevalent neurological condition affecting young adults is multiple sclerosis (MS), which often manifests as symptoms between the ages of 20 and 40. Myelin, also referred to as white matter, protects the central nervous system’s axons from damage in multiple sclerosis (MS).About 85% of MS patients have relapsing-remitting MS, which is the most prevalent type.

 

Get a Free Sample PDF Report to know more about Multiple Sclerosis Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

 

Emerging Multiple Sclerosis Drugs Under Different Phases of Clinical Development Include:

  • IMCY-0141: ImCyse
  • ATA188: Atara Biotherapeutics
  • EHP-101: Emerald Health Pharmaceuticals
  • SAR441344: Sanofi
  • RC18: RemeGen
  • GB7208: Gossamer Bio
  • MRx0002: 4D Pharma
  • HuL001: HuniLife Biotechnology
  • ANK-700: Anokion
  • GSK3888130: GSK plc
  • Temelimab: GeNeuro
  • IMU-838: Immunic Therapeutics
  • Tolebrutinib: Sanofi
  • Fenebrutinib: Hoffman-La-Roche

 

Multiple Sclerosis Route of Administration

Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Multiple Sclerosis Molecule Type

Multiple Sclerosis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Multiple Sclerosis Pipeline Therapeutics Assessment

  • Multiple Sclerosis Assessment by Product Type
  • Multiple Sclerosis By Stage and Product Type
  • Multiple Sclerosis Assessment by Route of Administration
  • Multiple Sclerosis By Stage and Route of Administration
  • Multiple Sclerosis Assessment by Molecule Type
  • Multiple Sclerosis by Stage and Molecule Type

 

DelveInsight’s Multiple Sclerosis Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Multiple Sclerosis product details are provided in the report. Download the Multiple Sclerosis pipeline report to learn more about the emerging Multiple Sclerosis therapies

 

Some of the key companies in the Multiple Sclerosis Therapeutics Market include:

Key companies developing therapies for Multiple Sclerosis are – Celgene, Actelion (now Janssen Pulmonary Hypertension), EMD Serono, Inc., Bayer, Acorda Therapeutics, Inc., Biogen, Teva Pharmaceuticals, Novartis, Sanofi, F. Hoffmann-La Roche Ltd, and others.

 

Multiple Sclerosis Pipeline Analysis:

The Multiple Sclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
  • Multiple Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Multiple Sclerosis drugs and therapies

 

Multiple Sclerosis Pipeline Market Drivers

  • Increasing Population with Multiple Sclerosis, extensive Approved therapies, wide range of R&D Pipeline, increasing Awareness are some of the important factors that are fueling the Multiple Sclerosis Market.

 

Multiple Sclerosis Pipeline Market Barriers

  • However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Multiple Sclerosis Market growth.

 

Scope of Multiple Sclerosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Multiple Sclerosis Companies: ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others
  • Key Multiple Sclerosis Therapies: IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others
  • Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies
  • Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers 

 

Request for Sample PDF Report for Multiple Sclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Multiple Sclerosis Report Introduction

2. Multiple Sclerosis Executive Summary

3. Multiple Sclerosis Overview

4. Multiple Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Multiple Sclerosis Pipeline Therapeutics

6. Multiple Sclerosis Late Stage Products (Phase II/III)

7. Multiple Sclerosis Mid Stage Products (Phase II)

8. Multiple Sclerosis Early Stage Products (Phase I)

9. Multiple Sclerosis Preclinical Stage Products

10. Multiple Sclerosis Therapeutics Assessment

11. Multiple Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Multiple Sclerosis Key Companies

14. Multiple Sclerosis Key Products

15. Multiple Sclerosis Unmet Needs

16 . Multiple Sclerosis Market Drivers and Barriers

17. Multiple Sclerosis Future Perspectives and Conclusion

18. Multiple Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda Therapeutics

Elevating Digital Excellence: Websiteranking.ai Unveils Revolutionary Path to Revenue Growth and Enhanced User Engagement

Surrey, Canada – Feb 21, 2024 – In the dynamic realm of digital business, owning a website extends beyond mere online existence to becoming a strategic asset pivotal for revenue growth and user engagement. However, the journey to transforming a website from a static presence to a dynamic, revenue-generating platform is fraught with challenges. Many enterprises find themselves entangled in the web of digital mediocrity, pondering over the real value of their online investments. Amidst this digital quandary, “If your website isn’t generating revenue, then what’s its purpose?” emerges as a critical reflection of the frustration pervading among business owners and marketers confronted with underachieving websites. Enter Websiteranking.ai, a ground breaking innovation designed to redefine the standards of website optimization.

Distinguished not merely as a tool but as a transformational force, Websiteranking.ai harnesses the power of advanced AI technology to chart a comprehensive, actionable plan aimed at dismantling the barriers that impede website performance. From enhancing user engagement and conversion rates to reducing bounce rates, Websiteranking.ai tailors its insights and strategies to meet the unique demands of your digital platform. This approach ensures that your website evolves into an influential business asset, optimized not just for function but for maximum impact.

At the core of Websiteranking.ai’s innovative strategy is the belief that a website should serve as more than a digital business card. It should be a vital, revenue-generating component of your business model. By prioritizing key performance metrics such as revenue and lead generation, along with user engagement, Websiteranking.ai empowers your website to significantly contribute to your business’s overarching goals.

One often overlooked yet critical factor in website optimization is adherence to the “3-second rule.” Research indicates that users form judgments and decide on the value of a website within the first three seconds of a visit. Failing to present the needed information within this narrow window can result in increased bounce rates and missed engagement opportunities. Websiteranking.ai meticulously optimizes your website to meet these user expectations, ensuring that every visitor is immediately engaged, thereby boosting the likelihood of conversion and retention.

Moreover, Websiteranking.ai recognizes the intricate relationship between website performance and search engine rankings. Employing SEO best practices and content optimization strategies, Websiteranking.ai enhances your website’s visibility, drawing more traffic and, by extension, creating more opportunities for revenue generation. This holistic approach not only elevates your website’s performance but also solidifies its position in the competitive digital marketplace.

Transition your online presence from a mere digital placeholder to a robust, revenue-driving powerhouse with Websiteranking.ai. Say farewell to the days of underperforming websites and embrace a future marked by digital excellence and business growth. Let Websiteranking.ai be your partner in navigating the complexities of website optimization, unlocking new avenues for success in the digital age.

Embark on your journey towards digital transformation and unlock the full potential of your website with Websiteranking.ai. For further information on how Websiteranking.ai can revolutionize your website’s performance, visit www.websiteranking.ai Email info@websiteranking.ai Phone : 604 999 2365

Media Contact
Company Name: websiteranking.ai
Contact Person: Anuj Sayal
Email: Send Email
Country: Canada
Website: https://www.websiteranking.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Elevating Digital Excellence: Websiteranking.ai Unveils Revolutionary Path to Revenue Growth and Enhanced User Engagement

Cavendish & Brown Wealth Management Unveils Tailored Strategies for Retiree Investor

Cavendish & Brown Wealth Management, a renowned leader in wealth management services founded by David Cavendish and John Brown, announces the launch of specialized investment strategies designed to meet the unique needs of retiree investors. With a significant portion of their clientele comprising retirees and individuals who haven’t invested in a long time, Cavendish & Brown leverages its decades of experience and expertise to offer tailored solutions that maximize returns while minimizing risk.

Retiree investors often face the challenge of generating sufficient income to support their lifestyle without depleting their savings. David Cavendish and John Brown, along with their team at Cavendish & Brown, understand the importance of preserving capital while seeking steady returns in retirement. Through a comprehensive analysis of each client’s financial situation, risk tolerance, and investment goals, Cavendish & Brown develops personalized strategies that prioritize income generation and capital preservation.

“Retirement should be a time of financial security and peace of mind,” remarked David Cavendish, Co-founder and Director of Cavendish & Brown. “At Cavendish & Brown, we are dedicated to helping retirees achieve their financial goals by providing them with tailored investment solutions that align with their unique needs and circumstances.”

John Brown, Co-founder and Director of Cavendish & Brown, added, “Many retirees may feel overwhelmed or uncertain about investing, especially if they haven’t done so in a long time. Our team specializes in guiding retirees through the investment process, offering clear explanations and personalized recommendations to help them make informed decisions about their financial future.”

Cavendish & Brown’s commitment to serving retiree investors underscores the firm’s dedication to providing comprehensive wealth management solutions that empower clients to enjoy a secure and fulfilling retirement.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Cavendish Brown
Contact Person: Public Relations
Email: Send Email
Country: Switzerland
Website: https://www.cavendishbrownwm.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cavendish & Brown Wealth Management Unveils Tailored Strategies for Retiree Investor

PeopleOne Health Joins Forces with the Health Transformation Alliance to Expand Access to No-cost Employee Healthcare

“PeopleOne Health logo”
PeopleOne Health announces an agreement with the Health Transformation Alliance, a national cooperative of leading companies committed to providing better healthcare for employees and their families.

PeopleOne Health–Health Transformation Alliance (HTA) agreement, which went into effect in August, aligns HTA-member organizations with the PeopleOne Health direct primary care model in communities in Pennsylvania and Ohio. The agreement gives HTA companies and their employees unlimited access to direct primary care via a straightforward, single-price model, featuring no copays, no deductibles and no unexpected bills.

In addition to patients receiving the benefits of extended doctor visits, PeopleOne Health provides onsite lab and consultative services, such as a care coordinator, onsite pharmacist and in-office access to more than 200 generic medications at no-cost.

“Like HTA, we are committed to mobilizing the shared interests of self-insured employers to drive greater access to preventative care, which help improve outcomes and reduce costs for employers and employees,” said Jordan Taradash, CEO, PeopleOne Health. “Both HTA and PeopleOne Health believe everyone deserves better healthcare and all Americans should have access to affordable, high-quality care. Self-insured employers, like those affiliated with the HTA, are committed to driving better health outcomes for employees and their families.”

HTA-member companies comprise a cross-section of more than 50 of America’s largest employers, which account for more than $27B in medical spending for their workforces.

The agreement between HTA and PeopleOne Health couldn’t come at a more crucial time.

Headlines are growing across the country about the extreme increases in employer health insurance – rising at its fastest rate in 2023 since 2011 – jumping by 7 percent for the cost of a family plan, a $24,000 bill. Workers paid, on average, nearly $500 more than in 2022.

Employers and employees are expected to see similar increases in 2024, according to many industry professionals, with premiums jumping 8.5 percent or more.

Employers are trying to hold the line by not passing increased costs onto employees, primarily by holding down deductibles – the out-of-pocket costs employees pay for care before their health plan coverage begins to pay the bill.

Experts believe employers have reached the limit in terms of how much of a premium increase they can shoulder or pass onto employees. Many companies are concerned the cost employees are bearing is causing employees to avoid needed care. That’s where PeopleOne Health is vital.

“As healthcare costs continue their march upward – stifling the growth of companies and the health of employees – PeopleOne Health is changing the game by giving families the confidence they deserve when it comes to their health,” said Mr. Taradash. “And, because our no-copay, no-deductible model was created to give families more, high-quality access to care, folks can leave their insurance cards at home and not worry about the cost of their care.”

About PeopleOne Health

PeopleOne Health is a leading provider organization committed to delivering high-quality, patient-centered healthcare services. With a focus on innovation and compassionate care, PeopleOne Health strives to improve health outcomes and enhance the well-being of individuals and communities.  

About Health Transformation Alliance

The Health Transformation Alliance (HTA) is a coalition of forward-thinking, self-insured employers dedicated to revolutionizing healthcare delivery. HTA collaborates with healthcare providers and stakeholders to develop innovative programs aimed at improving healthcare quality, reducing costs, and enhancing patient experiences.

Media Contact
Company Name: PeopleOne Health
Contact Person: Mark Weber
Email: Send Email
Phone: 412.951.0648
City: Pittsburgh
State: PA
Country: United States
Website: peopleonehealth.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PeopleOne Health Joins Forces with the Health Transformation Alliance to Expand Access to No-cost Employee Healthcare

MAREE Introduces New Eye Gel Pads with Natural Marine Ingredients for Enhanced Eye Care

MAREE introduces eye gel pads with marine collagen and natural extracts to tackle dark circles, puffiness, and wrinkles effectively.

MAREE LLC, a leader in marine-based skincare, announces the release of its latest product – the MAREE  Eye Gel Pads. This new offering aims to provide a gentle yet effective solution for those looking to address issues like puffy eyes, dark circles, and wrinkles. By leveraging the benefits of marine collagen, red algae, camellia japonica, and pearl extract, these eye gels offer targeted under-eye care designed to refresh and rejuvenate the skin.

The demand for effective eye care solutions has grown, as many individuals face challenges like tired eyes due to various factors, including stress, lack of sleep, and environmental influences. While the market offers numerous eye care products, finding ones that are both effective and free from harsh chemicals can be a challenge. MAREE’s Eye Gel Pads are presented as a solution that combines efficacy with natural ingredients, catering to those who prefer skincare products that are kind to their skin and the environment.

The formulation of the Eye Gel Pads focuses on the synergistic effects of its marine-based ingredients. Marine collagen is known for reducing the appearance of fine lines and wrinkles. Red algae extract contributes to skin hydration and brightness, while camellia japonica offers antioxidant benefits to protect and soothe the skin. Additionally, pearl extract is used for its properties that enhance skin tone and reduce dark circles.

The benefits of these eye gels include reduced puffiness, minimized eye bags, and a more hydrated and youthful skin appearance. They are designed to be user-friendly and are suitable for all skin types, making them a practical choice for anyone looking to improve their eye area.

MAREE has made these Eye Gel Pads available in packs of 12 pairs, each individually wrapped for ease of use and hygiene. Customers can find this product on Amazon, which is offered at a competitive price.

In line with its commitment to ethical practices, MAREE ensures that all its products, including the Eye Gel Pads, are cruelty-free, paraben-free, and sulfate-free. The brand also prioritizes environmental responsibility by using recyclable packaging materials, reflecting its dedication to offering skincare solutions that benefit both users and the planet.

With the introduction of the Eye Gel Pads, MAREE continues to expand its portfolio of marine-based skincare products. The brand remains focused on providing high-quality skincare options that meet the needs of its diverse customer base.

Users can learn more and get the MAREE Eye Gel Pads on Amazon.com

Media Contact
Company Name: MAREE LLC
Contact Person: Support
Email: Send Email
City: Casper
State: Wyoming
Country: United States
Website: www.amazon.com/stores/MAREE/page/5562A47C-7D38-4B9E-97B1-B1ECACA58213

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MAREE Introduces New Eye Gel Pads with Natural Marine Ingredients for Enhanced Eye Care

Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

DelveInsight’s, “Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Breast Cancer Pipeline Report

  • DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
  • The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
  • December 2023: Cancer Insight LLC announced a study of Phase 2 clinical trials for Trastuzumab and GM-CSF. In this study, the investigators intend to assess the ability of the combination of trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant GM-CSF) given in the adjuvant setting to prevent recurrences in patients with high-risk HER2-positive breast cancer. High-risk is defined as those patients that do not achieve a pCR after neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy or those who undergo upfront surgery and are found to have greater than or equal to four positive lymph nodes regardless of hormone receptor status or 1-3 positive lymph nodes and are hormone receptor negative.
  • December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib, Trastuzumab and Pertuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
  • December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide. This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

  

Request a sample and discover the recent advances in Breast Cancer Treatment Drugs @ Breast Cancer Pipeline Outlook Report

 

The Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Breast Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Breast Cancer clinical trial landscape.

 

Breast Cancer Overview

Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 in 10 new cancer diagnoses each year. It is the second most common cause of death from cancer among women in the world. Anatomically, the breast has milk-producing glands in front of the chest wall. They lie on the pectoralis major muscle, and there are ligaments support the breast and attach it to the chest wall. Fifteen to 20 lobes circularly arranged to form the breast.

 

Find out more about Breast Cancer Treatment Landscape @ Drugs for Breast Cancer Treatment

 

Breast Cancer Emerging Drugs Profile

  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  • HLX11: Shanghai Henlius Biotech
  • Praluzatamab ravtansine: CytomX Therapeutics
  • MCLA-128: Merus N.V.
  • DX126 262: Hangzhou DAC Biotech

 

Breast Cancer Pipeline Therapeutics Assessment

There are approx. 120+ key Breast Cancer companies which are developing the Breast Cancer therapies. The Breast Cancer companies which have their Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.

 

DelveInsight’s Breast Cancer pipeline report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Breast Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Breast Cancer Pipeline Therapies @ Breast Cancer Clinical Trials Assessment

 

Scope of the Breast Cancer Pipeline Report

  • Coverage- Global
  • Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

 

Dive deep into rich insights for new drugs for Breast Cancer treatment, Visit @ Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MCLA-128: Merus N.V.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DX126 262: Hangzhou DAC Biotech
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ES2B C001: ExpreS2ion Biotechnologies
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Breast Cancer Companies
  21. Breast Cancer Products
  22. Breast Cancer Unmet Needs
  23. Breast Cancer Market Drivers and Barriers
  24. Breast Cancer Future Perspectives and Conclusion
  25. Breast Cancer Analyst Views
  26. Breast Cancer Companies
  27. Appendix

 

For further information on the Breast Cancer pipeline therapeutics, reach out to Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2024” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Multiple Myeloma Pipeline Report

  • DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
  • The leading Multiple Myeloma Companies working in the market include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Promising Multiple Myeloma Pipeline Therapies in the various stages of development include TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
  • December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for Cevostamab, Tocilizumab, Pomalidomide, Daratumumab and Dexamethasone. This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
  • December 2023: AbbVieannounced a study of Phase 3 clinical trials for Pomalidomide, Dexamethasone and Venetoclax. A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 1 clinical trials for Linvoseltamab, Daratumumab, Carfilzomib, Bortezomib and Isatuximab. The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after multiple prior therapies and needed to be treated again.

 

Request a sample and discover the recent advances in Multiple Myeloma Treatment Drugs @ Multiple Myeloma Pipeline Outlook Report

 

The Multiple Myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Multiple Myeloma clinical trial landscape.

 

Multiple Myeloma Overview

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

 

Find out more about Multiple Myeloma Treatment Landscape @ Drugs for Multiple Myeloma Treatment

 

Multiple Myeloma Emerging Drugs Profile

  • Zevorcabtagene Autoleucel: Carsgen Therapeutics
  • Descartes 08: Cartesian Therapeutics
  • GC012F: Gracell Biotechnology Shanghai Co., Ltd.
  • CID-103: CASI Pharmaceuticals
  • STI-1492: Sorrento Therapeutics

 

Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 75+ key Multiple Myeloma companies which are developing the Multiple Myeloma therapies. The Multiple Myeloma companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e Registered include Carsgen Therapeutics.

 

DelveInsight’s Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Multiple Myeloma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Multiple Myeloma Pipeline Therapies @ Multiple Myeloma Clinical Trials Assessment

 

Scope of the Multiple Myeloma Pipeline Report

  • Coverage- Global
  • Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

 

Dive deep into rich insights for new drugs for Multiple Myeloma treatment, Visit @ Multiple Myeloma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Multiple myeloma Executive Summary
  3. Multiple myeloma Overview
  4. Multiple myeloma Pipeline Therapeutics
  5. Multiple myeloma Therapeutic Assessment
  6. Multiple myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Venetoclax: AbbVie
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. PHE885: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ONC 201: Oncoceutics
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. TNB 383B: TeneoBio
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple myeloma Companies
  21. Multiple myeloma Products
  22. Multiple myeloma Unmet Needs
  23. Multiple myeloma Market Drivers and Barriers
  24. Multiple myeloma Future Perspectives and Conclusion
  25. Multiple myeloma Analyst Views
  26. Multiple myeloma Companies
  27. Appendix

 

For further information on the Multiple Myeloma pipeline therapeutics, reach out to Multiple Myeloma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024